Monte Carlo simulation of radiation transport and dose deposition from locally released gold nanoparticles labeled with 111In, 177Lu or 90Y incorporated into tissue implantable depots

Phys Med Biol. 2017 Oct 27;62(22):8581-8599. doi: 10.1088/1361-6560/aa9106. ABSTRACT Permanent seed implantation (PSI) brachytherapy is a highly conformal form of radiation therapy but is challenged with dose inhomogeneity due to its utilization of low energy radiation sources. Gold nanoparticles (AuNP)…

Panitumumab Modified with Metal-Chelating Polymers (MCP) Complexed to 111In and 177Lu-An EGFR-Targeted Theranostic for Pancreatic Cancer

Mol Pharm. 2018 Mar 5;15(3):1150-1159. doi: 10.1021/acs.molpharmaceut.7b01000. Epub 2018 Jan 30. ABSTRACT A metal-chelating polymer (MCP) with a polyglutamide (PGlu) backbone presenting on average 13 DOTA (tetraazacyclododecane-1,4,7,10-tetraacetic acid) chelators for complexing 111In or 177Lu and 10 polyethylene glycol (PEG) chains…

Radioimmunotherapy of PANC-1 Human Pancreatic Cancer Xenografts in NRG Mice with Panitumumab Modified with Metal-Chelating Polymers Complexed to 177Lu

Mol Pharm. 2019 Feb 4;16(2):768-778. doi: 10.1021/acs.molpharmaceut.8b01040. Epub 2019 Jan 10. ABSTRACT Our aim was to evaluate the effectiveness and normal tissue toxicity of radioimmunotherapy (RIT) of s.c. PANC-1 human pancreatic cancer (PnCa) xenografts in NRG mice using anti-EGFR panitumumab…

Dual-Receptor-Targeted (DRT) Radiation Nanomedicine Labeled with 177Lu Is More Potent for Killing Human Breast Cancer Cells That Coexpress HER2 and EGFR Than Single-Receptor-Targeted (SRT) Radiation Nanomedicines

Mol Pharm. 2020 Apr 6;17(4):1226-1236. doi: 10.1021/acs.molpharmaceut.9b01259. Epub 2020 Mar 3. ABSTRACT Resistance to HER2-targeted therapies in breast cancer (BC) is associated in some cases with an increased expression of epidermal growth factor receptors (EGFR). We describe a dual-receptor-targeted (DRT)…

Radioimmunotherapy of human pancreatic cancer xenografts in NOD-scid mice with [64Cu]Cu-NOTA-panitumumab F(ab’)2 alone or combined with radiosensitizing gemcitabine and the PARP inhibitor, rucaparib

Nucl Med Biol. 2020 May-Jun;84-85:46-54. doi: 10.1016/j.nucmedbio.2020.02.001. Epub 2020 Feb 3. ABSTRACT INTRODUCTION: Our objective was to determine the feasibility of extending our previously reported PET imaging study of pancreatic cancer (PnCa) with Cu-NOTA-panitumumab F(ab’)2 to radioimmunotherapy (RIT) by exploiting…

Phase I/II Trial of the Combination of 177Lutetium Prostate specific Membrane Antigen 617 and Idronoxil (NOX66) in Men with End-stage Metastatic Castration-resistant Prostate Cancer (LuPIN)

Eur Urol Oncol. 2021 Dec;4(6):963-970. doi: 10.1016/j.euo.2020.07.002. Epub 2020 Aug 3. ABSTRACT BACKGROUND: Trials of lutetium prostate specific membrane antigen (PSMA) in men with metastatic castration-resistant prostate cancer (mCRPC) have demonstrated good safety and efficacy, but combination strategies may improve…

Combination of terbium-161 with somatostatin receptor antagonists-a potential paradigm shift for the treatment of neuroendocrine neoplasms

Eur J Nucl Med Mol Imaging. 2022 Mar;49(4):1113-1126. doi: 10.1007/s00259-021-05564-0. Epub 2021 Oct 8. ABSTRACT PURPOSE: The β¯-emitting terbium-161 also emits conversion and Auger electrons, which are believed to be effective in killing single cancer cells. Terbium-161 was applied with…

The association between lesion tracer uptake on 68Ga-DOTATATE PET with morphological response to 177Lu-DOTATATE therapy in patients with progressive metastatic neuroendocrine tumors

Nucl Med Commun. 2022 Jan 1;43(1):73-77. doi: 10.1097/MNM.0000000000001488. ABSTRACT PURPOSE: To determine in a group of patients with progressive metastatic neuroendocrine tumors (PM-NETs) treated with 177Lu-DOTATATE whether a correlation exists between somatostatin receptor (SSTR)-2 expression in various tumors on baseline…

Treatment of Orthotopic U251 Human Glioblastoma Multiforme Tumors in NRG Mice by Convection-Enhanced Delivery of Gold Nanoparticles Labeled with the β-Particle-Emitting Radionuclide, 177Lu

Mol Pharm. 2023 Jan 2;20(1):582-592. doi: 10.1021/acs.molpharmaceut.2c00815. Epub 2022 Dec 14. ABSTRACT In this study, we investigated convection-enhanced delivery (CED) of 23 ± 3 nm gold nanoparticles (AuNPs) labeled with the β-particle-emitting radionuclide 177Lu (177Lu-AuNPs) for treatment of orthotopic U251-Luc…